Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics Corp. (RDTCF) Financial Performance & Income Statement Overview
Explore the financials of Rapid Dose Therapeutics Corp. (RDTCF), including yearly and quarterly data on income, cash flow, and balance sheets.
Rapid Dose Therapeutics Corp. (RDTCF) Income Statement & Financial Overview
View the income breakdown for Rapid Dose Therapeutics Corp. RDTCF across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $668577.00 | $501689.00 | $515916.00 | $398994.00 |
| Cost of Revenue | $343552.00 | $231355.00 | $187920.00 | $1.009M |
| Gross Profit | $325025.00 | $270334.00 | $327996.00 | $256704.00 |
| Gross Profit Ratio | $0.49 | $0.54 | $0.64 | $0.64 |
| R&D Expenses | $48624.00 | $44086.00 | $26019.00 | $29516.00 |
| SG&A Expenses | $1.56M | $1.20M | $1.11M | $1.10M |
| Operating Expenses | $1.67M | $1.29M | $1.19M | $1.21M |
| Total Costs & Expenses | $2.01M | $1.52M | $1.37M | $1.35M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $338472.00 | $347755.00 | $242146.00 | $304033.00 |
| Depreciation & Amortization | $59646.00 | $48160.00 | $50215.00 | $82733.00 |
| EBITDA | -$1.28M | -$969000.00 | -$807000.00 | -$872000.00 |
| EBITDA Ratio | -$1.92 | -$1.93 | -$1.56 | -$2.19 |
| Operating Income | -$1.34M | -$1.02M | -$807298.00 | -$872000.00 |
| Operating Income Ratio | -$2.009 | -$2.03 | -$1.56 | -$2.19 |
| Other Income/Expenses (Net) | -$338472.00 | -$348000.00 | -$242000.00 | -$304000.00 |
| Income Before Tax | -$1.68M | -$1.36M | -$1.10M | -$1.26M |
| Income Before Tax Ratio | -$2.52 | -$2.72 | -$2.13 | -$3.15 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$3.00 |
| Net Income | -$1.68M | -$1.36M | -$1.10M | -$1.26M |
| Net Income Ratio | -$2.52 | -$2.72 | -$2.13 | -$3.15 |
| EPS | -$0.01 | -$0.01 | -$0.009 | -$0.01 |
| Diluted EPS | -$0.01 | -$0.01 | -$0.009 | -$0.01 |
| Weighted Avg Shares Outstanding | $129.53M | $124.17M | $123.12M | $121.76M |
| Weighted Avg Shares Outstanding (Diluted) | $129.53M | $124.17M | $123.12M | $121.76M |
Over the last four quarters, Rapid Dose Therapeutics Corp. achieved steady financial progress, growing revenue from $398994.00 in Q1 2024 to $668577.00 in Q4 2024. Gross profit stayed firm with margins at 49% in Q4 2024 versus 64% in Q1 2024. Operating income totaled -$1.34M in Q4 2024, maintaining a -201% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$1.28M. Net income dropped to -$1.68M, with EPS at -$0.01. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan